Want to see FR:ERF full AI Analyst Report?
Top Page
Eurofins Scientific
(ERF)
Select Model
Select Model
Rating:59Neutral
Price Target:
€81.00
▲(9.34% Upside)
Action:Reiterated
Date:08/06/26
The score is held back primarily by higher leverage, cash-flow softness, and margin volatility (including the sharp 2025 gross margin drop) despite strong 2025 revenue growth. Technicals are a positive offset given an uptrend across moving averages and healthy (not overbought) momentum, while valuation is middling with a ~22.7 P/E and a modest ~1.06% dividend yield.
Positive Factors
Diversified global laboratory services
Broad exposure across regulated testing markets reduces reliance on any single end market and supports resilience in demand. Eurofins’ laboratory network, specialized methods, and wide service offering can deepen customer relationships and create multiple avenues for sustained growth.
Negative Factors
Material increase in leverage
The sharp increase in leverage and accompanying equity decline reduce financial flexibility and make the business more sensitive to operating weakness. Higher debt can increase refinancing and interest burdens, potentially constraining investment and capital allocation over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified global laboratory services
Broad exposure across regulated testing markets reduces reliance on any single end market and supports resilience in demand. Eurofins’ laboratory network, specialized methods, and wide service offering can deepen customer relationships and create multiple avenues for sustained growth.
Read all positive factors
Eurofins Scientific (ERF) vs. iShares MSCI France ETF (EWQ)
Market Cap
€13.67B
Dividend Yield0.93%
Average Volume (3M)366.00K
Price to Earnings (P/E)25.9
Beta (1Y)0.85
Revenue Growth3.38%
EPS Growth28.21%
CountryFR
Employees65,000
SectorGeneral
Sector StrengthN/A
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)3.00
Shares Outstanding176,000,000
10 Day Avg. Volume348,923
30 Day Avg. Volume365,996
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)3.17
Price to Sales (P/S)1.54
P/FCF Ratio20.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€65.47Price Target Upside-11.63% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)4
Revenue Forecast (FY)€7.52B
Eurofins Scientific Business Overview & Revenue Model
Company Description
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. It provides services, such as agroscience, including biological assessment, consumer and human, environmental safety, pr...
How the Company Makes Money
Eurofins primarily makes money by providing fee-for-service laboratory testing and related scientific services to business and public-sector customers. Revenue is generated when clients submit samples (or commission on-site/field work where applic...
Eurofins Scientific Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
46
Neutral
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.38B | 7.30B | 6.95B | 6.51B | 6.71B | 6.72B |
| Gross Profit | 884.10M | 896.70M | 4.71B | 620.40M | 4.49B | 4.57B |
| EBITDA | 1.49B | 1.45B | 1.39B | 1.22B | 1.49B | 1.88B |
| Net Income | 530.40M | 475.00M | 406.40M | 310.30M | 610.20M | 782.60M |
Balance Sheet | ||||||
| Total Assets | 11.11B | 10.98B | 10.89B | 10.89B | 10.08B | 9.33B |
| Cash, Cash Equivalents and Short-Term Investments | 618.00M | 791.00M | 613.90M | 1.22B | 486.60M | 515.30M |
| Total Debt | 5.47B | 5.43B | 3.61B | 3.93B | 3.33B | 2.75B |
| Total Liabilities | 7.46B | 7.40B | 5.50B | 5.75B | 5.23B | 4.66B |
| Stockholders Equity | 3.62B | 3.54B | 5.34B | 5.08B | 4.78B | 4.65B |
Cash Flow | ||||||
| Free Cash Flow | 634.90M | 535.00M | 790.50M | 467.80M | 476.10M | 990.30M |
| Operating Cash Flow | 1.36B | 1.29B | 1.32B | 1.02B | 1.14B | 1.51B |
| Investing Cash Flow | -1.03B | -1.09B | -846.50M | -681.10M | -855.90M | -1.03B |
| Financing Cash Flow | -455.20M | 13.00M | -1.09B | 413.60M | -311.30M | -910.30M |
Eurofins Scientific Technical Analysis
Positive
74.08
Price Trends
73.36
Positive
69.89
Positive
67.19
Positive
Market Momentum
0.97
Positive
59.95
Neutral
66.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ERF, the sentiment is Positive. The current price of 74.08 is below the 20-day moving average (MA) of 76.39, above the 50-day MA of 73.36, and above the 200-day MA of 67.19, indicating a bullish trend. The MACD of 0.97 indicates Positive momentum. The RSI at 59.95 is Neutral, neither overbought nor oversold. The STOCH value of 66.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ERF.
Eurofins Scientific Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | €12.08B | 23.89 | 29.90% | 3.38% | 1.88% | -22.65% | |
71 Outperform | €9.95B | 21.44 | 11.01% | 1.16% | -3.18% | 22.52% | |
69 Neutral | €2.66B | 17.07 | 13.31% | 0.46% | 4.30% | 17.11% | |
62 Neutral | €20.71B | 70.46 | 7.11% | 0.32% | 3.76% | 29.94% | |
59 Neutral | €13.67B | 25.89 | 14.81% | 0.93% | 3.38% | 28.21% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
FR:ERF
Eurofins Scientific
77.66
16.64
27.28%
FR:BIM
bioMerieux
84.25
-23.57
-21.86%
FR:BVI
Bureau Veritas
27.23
1.01
3.87%
FR:DIM
Sartorius Stedim Biotech
212.80
26.46
14.20%
FR:VIRP
Virbac SA
317.00
3.88
1.24%
FR:ALBIO
Biosynex SA
0.83
0.16
23.15%
Eurofins Scientific Corporate Events
Eurofins Scientific Buys Back 170,000 Shares in October Transactions
Oct 12, 2026
Eurofins Scientific has executed a series of share repurchases between 5 and 9 October 2026 across the Paris (XPAR) and Cboe Europe (CEUX) markets, buying a total of 170,000 shares at a weighted average price of €76.41. The transactions, car...
Eurofins Updates Voting Rights After Buybacks and Unit Cancellations
Oct 6, 2026
Eurofins Scientific has disclosed updated capital and voting rights information, confirming a share capital of 176 million shares and a total of 360,234,148 voting rights attached to those shares. The change reflects a reduction in voting rights s...
Eurofins Sells MET Labs to UL Solutions to Refocus on Core Life-Science Testing
Oct 2, 2026
Eurofins Scientific has completed the sale of its Electrical Electronic Testing business, MET Labs, to UL Solutions for an enterprise value of €575 million, with closing on 1 October 2026. MET Labs, an international network of labs with abo...
Eurofins Steps Up Share Buy-Back Activity Across European Trading Venues
Sep 21, 2026
Eurofins Scientific, a major European-listed provider of laboratory testing and analytical services to pharmaceutical, food, environmental, and clinical diagnostics markets, maintains an active trading presence on Euronext Paris and several multil...
Eurofins Updates Voting Rights Following Cancellation of Units and Share Buybacks
Sep 10, 2026
Eurofins Scientific SE has disclosed an updated total of 362,395,012 voting rights attached to its 176,000,000 shares, in line with transparency requirements under Luxembourg law. The change results from the cancellation of certain class A benefic...
Eurofins Steps Up Capital Management With August Share Buy-Back
Aug 10, 2026
Eurofins Scientific SE disclosed recent transactions under its share buy-back programme, reporting the repurchase of a total of 100,000 shares on the Paris market between 3 and 7 August 2026 at a daily weighted average price of €69.3844. The...
Eurofins Updates Share Capital and Voting Rights After Buybacks and Unit Cancellations
Aug 10, 2026
Eurofins Scientific SE has disclosed an updated total of 176,000,000 shares in issue, corresponding to 362,789,717 voting rights attached to its share capital under Luxembourg transparency regulations. The change in voting rights stems from the ca...
Eurofins Scientific Discloses Late-July Share Buybacks Totalling 110,000 Shares
Aug 3, 2026
Eurofins Scientific disclosed a series of share repurchases carried out between 27 July and 31 July 2026 across the XPAR and CEUX markets, buying a total of 110,000 shares at a daily weighted average price of EUR 67.93. The buybacks, conducted und...
Eurofins Details July Share Buy-Back Transactions
Jul 27, 2026
Eurofins Scientific disclosed a series of share repurchases carried out between 20 and 24 July 2026 across Euronext Paris and Cboe Europe, covering 85,000 shares at a daily weighted average purchase price of about €68.33 under its ongoing bu...
Eurofins Boosts Profits, Cash Flow and Life Sciences Focus in Strong H1 2026
Jul 23, 2026
Eurofins reported a strong first half of 2026, with basic EPS up 29% to €1.55 and revenues rising 2.5% to €3.7 billion despite currency headwinds, as benefits from its long-term investment in laboratory networks and digitalisation flow...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.